davunetide
Peptideexperimental
Clinical trial activity
5 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2006 (NCT00404014)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Microtubule-associated protein tauINHIBITOR
MAPT inhibitor
- TubulinSTABILISER
Tubulin stabiliser
Interacts with the Tubulin heterodimer, but shows preference to Tubulin beta III in neurons.
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O- Mol. weight
- 824.93 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103826 ↗
Also known as
- al 108
- al-108
- al-108
- al-108
- al-108
- al108 cpd
- al 208
- al-208
- al-208
- al-208
- al-208
- al208 cpd
- al-408
- davunetide
- davunetide
- davunetide
- davunetide
- davunetide
- d-nap peptide
- nap peptide
- napvsipq peptide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01110720 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2010 | Allon Therapeutics, University of California, San Francisco |
| NCT01056965 | Phase 2 | Jan 1, 2010 | University of California, San Francisco |
| NCT00505765 | Phase 2 | Jul 1, 2007 | Columbia University, Duke University, Harvard University, New York University, University of California, Los Angeles, University of Maryland, Washington University in St. Louis |
| NCT00422981 | Phase 2 | Jan 1, 2007 | Allon Therapeutics |
| NCT00404014 | Phase 2 | Aug 1, 2006 | Allon Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allon Therapeutics | For profit | 3 | 3 | 2 | 2006 |
| University of California, San Francisco | Academic/Hospital | 2 | 1 | 2 | 2010 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2007 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2007 |
9 organizations
Page 1 / 1